NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 18, Pages E2526-E2535
Publisher
Proceedings of the National Academy of Sciences
Online
2016-04-19
DOI
10.1073/pnas.1522612113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
- (2015) A. Bertotti et al. CLINICAL CANCER RESEARCH
- Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient
- (2015) Matthias Scheffler et al. Journal of Thoracic Oncology
- EGFR and NF-κB: partners in cancer
- (2015) Kateryna Shostak et al. TRENDS IN MOLECULAR MEDICINE
- Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
- (2014) Akiko Murakami et al. PLoS One
- Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation
- (2014) Theodore Hu et al. Scientific Reports
- -Catenin/POU5F1/SOX2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma
- (2013) C. Xu et al. CANCER RESEARCH
- Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells
- (2013) K. Shien et al. CANCER RESEARCH
- STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma
- (2013) Katharina Kopp et al. CELL CYCLE
- Stem cell-like ALDHbrightcellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
- (2013) BRUNA COROMINAS-FAJA et al. CELL CYCLE
- Epidermal growth factor receptor mutations in lung adenocarcinoma
- (2013) Markus D Siegelin et al. LABORATORY INVESTIGATION
- MiR-155 at the heart of oncogenic pathways
- (2013) M F Czyzyk-Krzeska et al. ONCOGENE
- MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer
- (2013) J Johansson et al. ONCOGENE
- Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer
- (2013) W Kong et al. ONCOGENE
- miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit
- (2013) Yong Chen et al. Nature Communications
- A miRNA machinery component DDX20 controls NF-κB via microRNA-140 function
- (2012) Akemi Takata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776
- (2012) Yung-Luen Yu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer
- (2012) Sandeep Singh et al. Molecular Cancer
- In cancer drug resistance, germline matters too
- (2012) Emily H Cheng et al. NATURE MEDICINE
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol
- (2012) Y-H Yu et al. ONCOGENE
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators
- (2011) Akemi Takata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer
- (2011) Rosario Perona et al. Clinical & Translational Oncology
- Neurotensin Signaling Activates MicroRNAs-21 and -155 and Akt, Promotes Tumor Growth in Mice, and Is Increased in Human Colon Tumors
- (2011) Kyriaki Bakirtzi et al. GASTROENTEROLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Vienna Ludovini et al. Journal of Thoracic Oncology
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- I B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia
- (2010) N. Chapuis et al. BLOOD
- De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
- (2010) Masayuki Takeda et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- MicroRNA-155 Is Regulated by the Transforming Growth Factor /Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA
- (2008) W. Kong et al. MOLECULAR AND CELLULAR BIOLOGY
- MicroRNAs: new regulators of immune cell development and function
- (2008) David Baltimore et al. NATURE IMMUNOLOGY
- Analyzing real-time PCR data by the comparative CT method
- (2008) Thomas D Schmittgen et al. Nature Protocols
- FOXOs, cancer and regulation of apoptosis
- (2008) Z Fu et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search